Not just asleep at the wheel, but have abandoned the controls...

Not just asleep at the wheel, but have abandoned the controls altogether to go and take a long lunch and hatch a plan to increase their bonuses.

There are plenty of opportunities for ACR.

1. Most countries globally are not as nervous about the health impacts of Testosterone as the US FDA. Europe is much less concerned.

2. In the US, you would expect that some patients with low testosterone will be annoyed about this. Perhaps Axiron can make a comeback after somebody else fights the battle with the FDA for us.

3. Marketing of Evamist outside its current availability in Europe.

Of course opportunity comes dressed in overalls and looks like hard work.

So they probably can't be bothered.